Skip to content
Open access

Экономическое бремя сахарного диабета 2-го типа в Российской Федерации: вклад осложнений и роль медицинской реабилитации (аналитический обзор)

Oct 2026 · Problems of Balneology, Physiotherapy and Exercise Therapy · 0 citations · 8 references

Abstract

Introduction: Type 2 diabetes mellitus (T2DM) represents a major economic burden for healthcare systems. As of 1 January 2026, the Federal Diabetes Register included 5.81 million patients, of whom 5.37 million (92.3%) had T2DM; adjusted for undiagnosed cases, the real prevalence is estimated at 10–12 million. T2DM without complications is not a classic indication for medical rehabilitation, yet its complications — vascular events, diabetic foot syndrome, nephropathy, retinopathy, neuropathy — form a large pool of patients requiring prolonged multidisciplinary rehabilitation. The economic dimension of this link has not been systematically summarized. Objective: To assess the economic burden of T2DM in the Russian Federation with a focus on the contribution of complications and to substantiate the role of medical rehabilitation in reducing this burden. Materials and methods: Data from the Federal Diabetes Register and the Endocrinology Research Centre, results of the NATION epidemiological study, published cost-of-illness and pharmacoeconomic studies, clinical guidelines and regulatory acts for 2016–2025 were used. Methods of economic-statistical, structural and dynamic analysis, cost-effectiveness analysis (CER, ICER) and the quality-adjusted life year (QALY) concept were applied. No author-constructed indices were introduced; all figures are reported from official and published sources. Results: As of 01.01.2026, 5.37 million people had T2DM; 51.1% of deaths in T2DM are due to circulatory diseases. Microvascular complications are common: nephropathy (chronic kidney disease) 23.1%, neuropathy 22.9%, retinopathy 10.7%; the pool of patients with diabetes at high cardiovascular risk (atherosclerotic disease, heart failure, kidney disease, amputations) reaches 1.91 million. Published estimates put the burden of T2DM (2014 data) at about 569 billion rubles, of which 426.7 billion were non-medical losses from temporary disability, disability and premature mortality; according to the FORSIGHT-DM2 study, 53.5% of the cost of illness are indirect losses, 57% of direct medical costs are spent on complications and only about 10% on glucose-lowering therapy, while inpatient treatment of complications per patient per year is about 6 times more expensive than in uncomplicated T2DM. A target HbA1c <7% is achieved by 48.4% of patients; metformin predominates in monotherapy (71.6%), and the share of sulfonylureas has fallen from 41.1% (2017) to 14.6%. The prescription rate of SGLT2 inhibitors has risen to 21.5%, reaching 40.1% in heart failure. About 0.64% of patients with coronary heart disease are involved in cardiac rehabilitation programs, whereas structured secondary prevention reduces cardiovascular events by 33–48%. Conclusion: The greatest economic effect is achieved not by lowering the price of therapy but by preventing complications and preserving function. Medical rehabilitation (cardiometabolic, after vascular events, in diabetic foot syndrome and amputations), together with disease-modifying therapy using classes with cardio- and nephroprotection, postpones disability and reduces costly hospitalizations. The main reserve is the routing of rehabilitation for diabetic patients and the expansion of its coverage.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.